Madrigal Pharmaceuticals, Inc. (MDGL) Social Stream
MADRIGAL PHARMACEUTICALS INC (MDGL) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering MADRIGAL PHARMACEUTICALS INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-12 | 11 | $203 | $145 | $174.5 | $300.64 | -41.96% |
| 2021-12-30 | 10 | $203 | $145 | $173.714 | $300.64 | -42.22% |
| 2022-02-25 | 9 | $203 | $131 | $167.571 | $300.64 | -44.26% |
| 2022-05-11 | 10 | $203 | $129 | $161.5 | $300.64 | -46.28% |
| 2022-05-12 | 10 | $203 | $129 | $156.25 | $300.64 | -48.03% |
| 2022-05-26 | 9 | $203 | $129 | $156.25 | $300.64 | -48.03% |
| 2022-08-04 | 9 | $203 | $75 | $149.25 | $300.64 | -50.36% |
| 2022-09-02 | 8 | $203 | $75 | $149.25 | $300.64 | -50.36% |
| 2022-11-10 | 7 | $203 | $75 | $141.875 | $300.64 | -52.81% |
| 2022-12-07 | 8 | $203 | $75 | $141.875 | $300.64 | -52.81% |
| 2022-12-20 | 10 | $280 | $75 | $151.5 | $300.64 | -49.61% |
| 2022-12-21 | 11 | $375 | $194 | $289.75 | $300.64 | -3.62% |
| 2023-01-05 | 11 | $390 | $194 | $296.25 | $300.64 | -1.46% |
| 2023-01-06 | 11 | $390 | $194 | $303 | $300.64 | 0.78% |
The Trend in the Analyst Price Target
MDGL's average price target has moved up $133 over the prior 24 months.
MDGL reports an average of 93.02% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-02-25 | 9 | 203 | 131 | 167.571 | 93.53 | 79.16% |
| 2022-10-23 | 8 | 203 | 75 | 141.875 | 67.63 | 109.78% |
| 2022-11-03 | 7 | 203 | 75 | 141.875 | 66.58 | 113.09% |
| 2022-12-20 | 11 | 375 | 92 | 250.300 | 250.00 | 0.12% |
| 2022-12-21 | 11 | 375 | 194 | 289.750 | 289.43 | 0.11% |
MDGL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.36 | 9 | 0 | 2 | 0 | 0 | 11 |
The Trend in the Broker Recommendations
Over the past 28 months, MDGL's average broker recommendation rating improved by 0.26.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MDGL as an investment opportunity.
- In the context of all US stocks, MADRIGAL PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 48.86% of them.
- In terms of how MADRIGAL PHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its average analyst price target is higher than 1632.75% of that group.
- MADRIGAL PHARMACEUTICALS INC's number of analysts covering the stock is higher than 1263.3% of stocks in the mid market cap category.
- MADRIGAL PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1005.56% of stocks in the mid market cap category.
Stocks similar to MADRIGAL PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are MGNX, CYRX, and CMRX.
View All Top Stocks by Price Target
Make investment decisions regarding MDGL using the data that counts. Try POWR Ratings for free.